{"id":30865,"date":"2016-11-29T09:14:41","date_gmt":"2016-11-29T09:14:41","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=30865"},"modified":"2016-11-29T17:57:24","modified_gmt":"2016-11-29T17:57:24","slug":"gsk-discontinues-development-of-maturation-inhibitor-bms-986173","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/30865","title":{"rendered":"GSK discontinues development of maturation inhibitor BMS-955176"},"content":{"rendered":"<p><strong>Simon Collins, HIV i-Base<\/strong><\/p>\n<p><strong>On 26 October 2016, a pharmaceutical news list announced that GSK will stop development of the lead maturation inhibitor BMS-955176.<\/strong> [1]<\/p>\n<p>This compound was acquired from Bristol-Myers Squibb last year and was already in phase 2b studies.<\/p>\n<p>The announcement was made by GSK CEO Andrew Witty on a routine quarterly earnings call but has not yet been announced more formally.<\/p>\n<p>The decision to end the development programme early was based on 24-week results from study AI468-038, a Phase 2b dose finding study in treatment naive patients, because of gastrointestinal intolerability and treatment-emergent drug resistance. [2]<\/p>\n<p>The ongoing studies with BMS-955176 (AI468-038 and AI468-048) will end early.<\/p>\n<p>Other earlier stage molecules were also acquired when GSK bought the BMS preclinical HIV pipeline in December 2015. This included a second maturation inhibitor in earlier development (BMS-986173) which will continue to be developed.<\/p>\n<h3>Comment<\/h3>\n<p><strong>This is disappointing news as maturation inhibitors would expect to be active about HIV that is multi-drug resistant to HIV medicines from other classes.<\/strong><\/p>\n<p><strong>The announcement referred to continuing development of two other maturation inhibitor compounds. As these are at earlier stages of development, this will set back the timeline for access.<\/strong><\/p>\n<p>References:<\/p>\n<ol>\n<li>Lawrence S. GSK drops a pair of late-stage candidates in COPD. FierceBiotec.com (26 October 2016).<br \/>\n<a href=\"http:\/\/www.fiercebiotech.com\/biotech\/gsk-drops-a-pair-late-stage-candidates-copd-hiv\">http:\/\/www.fiercebiotech.com\/biotech\/gsk-drops-a-pair-late-stage-candidates-copd-hiv<\/a><\/li>\n<li>Personal communication, ViiV Healthcare (31 October 2016).<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base On 26 October 2016, a pharmaceutical news list announced that GSK will stop development of the lead maturation inhibitor BMS-955176. [1] This compound was acquired from Bristol-Myers Squibb last year and was already in phase 2b &hellip;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-30865","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/30865","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=30865"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/30865\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=30865"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=30865"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=30865"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}